Table 3 Top five regimens and their time to discontinuation

First-line regimen

14,505 (100.0)

12,811 (100.0)

1,694 (100.0)

2.9 (2.7)

2.8 (2.5)

3.0 (4.0)

 Paclitaxel + platinum

4,758 (32.8)

4,387 (34.2)

371 (21.9)

2.8 (2.9)

2.8 (2.9)

2.5 (2.8)

 Pemetrexed + platinum

4,063 (28.0)

3,763 (29.4)

300 (17.7)

2.7 (1.3)

2.7 (1.3)

2.6 (1.1)

 Gemcitabine + platinum

4,042 (27.9)

3,631 (28.3)

411 (24.3)

2.9 (2.7)

2.9 (2.4)

3.1 (4.3)

 Gemcitabine

430 (3.0)

337 (2.6)

93 (5.5)

2.8 (4.8)

2.8 (5.2)

2.6 (3.0)

 Docetaxel + platinum

329 (2.3)

295 (2.3)

34 (2.0)

3.1 (2.1)

3.2 (2.1)

2.2 (1.7)

 Others

883 (6.1)

398 (3.1)

485 (28.6)

3.6 (4.9)

3.4 (4.1)

3.7 (5.4)

Second-line regimen

5.973 (100.0)

5,314 (100.0)

659 (100.0)

3.8 (4.9)

3.7 (4.9)

3.8 (5.1)

 Docetaxel

1,127 (18.9)

996 (18.7)

131 (19.9)

2.4 (2.3)

2.4 (2.3)

2.3 (1.9)

 Gemcitabine + platinum

946 (15.8)

860 (16.2)

86 (13.1)

2.6 (2.3)

2.6 (2.4)

2.5 (1.9)

 Pembrolizumab

822 (13.8)

765 (14.4)

57 (8.7)

7.0 (7.6)

6.9 (7.5)

8.7 (8.6)

 Nivolumab

688 (11.5)

617 (11.6)

71 (10.8)

6.0 (7.0)

5.9 (6.9)

6.6 (8.1)

 Paclitaxel + platinum

404 (6.8)

373 (7.0)

31 (4.7)

2.7 (3.9)

2.7 (3.8)

3.3 (5.3)

 Others

1,986 (33.3)

1,703 (32.1)

283 (42.9)

3.2 (3.9)

3.1 (3.8)

3.3 (3.9)